Trial Profile
A Phase 3 open label randomized multicenter trial to assess the efficacy and safety of the dispersible arterolane maleate 37.5 mg and piperaquine phosphate (PQP) 187.5 mg tablets in comparison with Coartem dispersible in pediatric patients with acute uncomplicated Plasmodium falciparum malaria
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2019
Price :
$35
*
At a glance
- Drugs Arterolane/piperaquine (Primary) ; Artemether/lumefantrine
- Indications Malaria
- Focus Registrational; Therapeutic Use
- Sponsors Sun Pharmaceutical Industries
- 19 Oct 2017 New trial record
- 29 Aug 2017 Results published in the Clinical Infectious Diseases